Spero Therapeutics, Inc. (SPRO)
2.33
+0.06
(+2.64%)
USD |
NASDAQ |
Dec 31, 16:00
2.32
-0.01
(-0.43%)
After-Hours: 20:00
Spero Therapeutics Cash from Financing (Quarterly): 0.00 for Sept. 30, 2025
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | -2.169M |
| Amicus Therapeutics, Inc. | -1.319M |
| Cassava Sciences, Inc. | 0.00 |
| Omeros Corp. | 25.82M |
| GeoVax Labs, Inc. | 8.127M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 17.42M |
| Free Cash Flow | -27.67M |
| Free Cash Flow Per Share (Quarterly) | 0.3096 |
| Free Cash Flow to Equity (Quarterly) | 17.69M |
| Free Cash Flow to Firm (Quarterly) | 17.42M |
| Free Cash Flow Yield | -21.38% |